0RA9.L - ABIVAX Société Anonyme

LSE - LSE Delayed price. Currency in EUR

ABIVAX Société Anonyme

7-11 boulevard Haussmann
Paris 75009
33 1 53 83 08 41

Full-time employees22

Key executives

NameTitlePayExercisedYear born
Dr. Philippe Pouletty M.D., Ph.D.Founder & DirectorN/AN/A1958
Mr. Marc M. P. de Garidel M.B.A.CEO & Interim Chair of BoardN/AN/A1958
Mr. Didier BlondelEVP, CFO & Board Sec.N/AN/AN/A
Ms. Raquel LizarragaInvestor Relations Mang.N/AN/AN/A
Ms. Regina JehleVP of CommunicationsN/AN/AN/A
Anne PascardHR Mang.N/AN/AN/A
Mr. Pierre Courteille M.B.A.Chief Bus. OfficerN/AN/AN/A
Mr. Sheldon SloanChief Medical OfficerN/AN/AN/A
Mr. Michael Ferguson B.S., M.B.A.Chief Commercial OfficerN/AN/AN/A
Mr. Paul GinesteVP Clinical OperationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that modulate the body's natural immune system to treat patients with chronic inflammatory, infectious, and cancer diseases. The company's products include obefazimod that is in Phase III clinical trials for the treatment of ulcerative colitis; Phase IIb clinical trials for the treatment of Crohn's Disease; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and in a pre-clinical trial for the treatment of Respiratory Syncytial Virus. It also develops ABX 196, an immune enhancer candidate that is in Phase 2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue, influenza, and respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Corporate governance

ABIVAX Société Anonyme’s ISS governance QualityScore as of 1 May 2023 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.